| Bioactivity | BMY 42393 is an orally active prostacyclin agonist which suppresses monocyte-macrophage atherogenic activity and cytokine production. BMY 42393 can be used for atherosclerosis research[1]. |
| In Vivo | BMY 42393 (30 mg/kg/d, 饮食, 10 周) 在接受轻度致动脉粥样硬化饮食的仓鼠中抑制 35% 的单核细胞黏附，使每平方毫米的泡沫细胞减少 44%，使泡沫细胞体积缩小 26%，使脂肪条纹面积缩小 40%，使内膜油红 O 染色减少 39%[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 136451-58-6 |
| Formula | C25H21NO4 |
| Molar Mass | 399.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kowala MC, et al. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. Arterioscler Thromb. 1993 Mar;13(3):435-44. |